New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
07:07 EDTEBSEmergent BioSolutions initiates Phase 2 study to evaluate BioThrax
Emergent BioSolutions announced the initiation of a Phase 2 study designed to evaluate non-interference of BioThrax when administered in conjunction with antibiotics. This non-interference study will be used to support a supplemental Biologics License Application seeking licensure of a Post-Exposure Prophylaxis indication for BioThrax to be used in combination with antibiotics in people suspected to have been exposed to anthrax spores. The primary objective of this Phase 2 study is to evaluate any impact of the vaccine on ciprofloxacin by administering the antibiotic prior to and following the administration of a 3-dose series of BioThrax. Preliminary data from this study are expected in the fourth quarter of 2013.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
14:50 EDTEBSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use